Literature DB >> 8326147

Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin.

F D Malkinson1, L Geng, W R Hanson.   

Abstract

Several years ago we showed that prostaglandins (PGs) are potent radioprotective agents. To investigate further the potential use of these compounds we employed quantitative measures of murine hair loss and regrowth to assess the effects of PG administration before multi-dose fractionated radiation exposures. We compared these results with findings utilizing the thiol compounds WR-2721 or WR-1065, the "gold standard" laboratory radioprotectors. Three weeks after systemic administration of 16-16 dm PGE2 (Upjohn Company) or WR-2721, given 1 h before each dose of 2-4.5 Gy per fraction for 10-15 fractions, regrowing hair counts increased up to 100% compared to irradiated-only skin sites. The thiol compound effects were slightly superior to the PG effects in these studies. Local applications of 16-16 dm PGE2 or WR-1065 given 15 min before each radiation fraction also enhanced post-radiation hair regrowth, although systemic administration of either agent was more effective than the topical route. We also evaluated possible protective effects of PGs given before doxorubicin, measuring murine hair loss 1 week after parenteral injections of the drug. Five daily doses of doxorubicin, 0.1 mg/25 g animal, reduced the number of hairs in a 4.42 mm2 area of skin from 241 +/- 5 (controls) to 144 +/- 3. Misoprostol (G.D. Searle & Co.), 25 micrograms/mouse, applied locally 2 h before each dose of doxorubicin, resulted in 213 +/- 8 residual hairs. We conclude that clinical use of these compounds may provide significant protection of hair follicles and possibly other normal tissues (skin; oral, rectal, and bladder mucosa) lying within a radiation field or in patients treated with chemotherapeutic agents. Further assessment of possible tumor protection effects are needed, however.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326147     DOI: 10.1111/1523-1747.ep12363200

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Authors:  Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

2.  Modulation of pro-inflammatory and pro-resolution mediators by γ-linolenic acid: an important element in radioprotection against ionizing radiation.

Authors:  Rangachar Poorani; Anant N Bhatt; Undurti N Das
Journal:  Arch Med Sci       Date:  2020-01-29       Impact factor: 3.318

3.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

4.  Annurca Apple Polyphenols Protect Murine Hair Follicles from Taxane Induced Dystrophy and Hijacks Polyunsaturated Fatty Acid Metabolism toward β-Oxidation.

Authors:  Gennaro Riccio; Eduardo Sommella; Nadia Badolati; Emanuela Salviati; Sara Bottone; Pietro Campiglia; Monica Dentice; Gian Carlo Tenore; Mariano Stornaiuolo; Ettore Novellino
Journal:  Nutrients       Date:  2018-11-20       Impact factor: 5.717

5.  Role of Arachidonic Acid in Promoting Hair Growth.

Authors:  Semchin Munkhbayar; Sunhyae Jang; A-Ri Cho; Soon-Jin Choi; Chang Yup Shin; Hee Chul Eun; Kyu Han Kim; Ohsang Kwon
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

Review 6.  Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges.

Authors:  Stefania Zuppone; Andrea Bresolin; Antonello E Spinelli; Giuseppe Fallara; Roberta Lucianò; Federico Scarfò; Fabio Benigni; Nadia Di Muzio; Claudio Fiorino; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Riccardo Vago; Cesare Cozzarini
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.